دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening
Matthew W. Martinez, MD1,2,3,4; Andrew M. Tucker, MD4,5; O. Josh Bloom, MD, MPH6; Gary Green, MD7,8; John P. DiFiori, MD9,10; Gary Solomon, PhD11,12,13,14; Dermot Phelan, MD, PhD15; Jonathan H. Kim, MD, MSc16; Willem Meeuwisse, MD, PhD17; Allen K. Sills, MD11,12,13,14,18; Dana Rowe, BA7; Isaac I. Bogoch, MD19; Paul T. Smith, MD20; Aaron L. Baggish, MD21; Margot Putukian, MD3; David J. Engel, MD22
doi : 10.1001/jamacardio.2021.0565
JAMA Cardiol. 2021;6(7):745-752
The major North American professional sports leagues were among the first to return to full-scale sport activity during the coronavirus disease 2019 (COVID-19) pandemic. Given the unknown incidence of adverse cardiac sequelae after COVID-19 infection in athletes, these leagues implemented a conservative return-to-play (RTP) cardiac testing program aligned with American College of Cardiology recommendations for all athletes testing positive for COVID-19.
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease
Katharina Mayer, MD1; Ralph Hein-Rothweiler, MD2; Stefanie Schüpke, MD1,3; Marion Janisch, MD1; Isabell Bernlochner, MD3,4; Gjin Ndrepepa, MD1; Dirk Sibbing, MD2,3,5; Tommaso Gori, MD6,7; Oliver Borst, MD8; Stefan Holdenrieder, MD9; Danny Kupka, MD2; Tobias Petzold, MD2; Christian Bradaric, MD4; Rainer Okrojek, MD4; David M. Leistner, MD10,11; Tobias D. Trippel, MD11,12; Thomas Münzel, MD6,7; Ulf Landmesser, MD10,11; Burkert Pieske, MD11,12; Andreas M. Zeiher, MD7,13; Meinrad P. Gawaz, MD8; Alexander Hapfelmeier, DSc14,15; Karl-Ludwig Laugwitz, MD3,4; Heribert Schunkert, MD1,3; Adnan Kastrati, MD1,3; Steffen Massberg, MD2,3
doi : 10.1001/jamacardio.2021.0475
JAMA Cardiol. 2021;6(7):753-761
The assessment of new antithrombotic agents with a favorable safety profile is clinically relevant.
Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction
Andrew J. Boyle, MBBS, PhD1,2,3; Carl Schultz, MBChB, DPhil4,5; Joseph B. Selvanayagam, MBBS, DPhil6,7; Stuart Moir, MBBS, PhD8,9; Richard Kovacs, MD10; Nabil Dib, MD11; David Zlotnick, MD12; Mohammed Al-Omary, MBBS1,2,3; Stuart Sugito, BMed, MPH1; Aravinda Selvarajah, MBBS1; Nicholas Collins, BMed1,2,3; Grant McLachlan, PhD13
doi : 10.1001/jamacardio.2021.0676
JAMA Cardiol. 2021;6(7):762-768
After anterior ST-segment elevation myocardial infarction (STEMI), left ventricular (LV) remodeling results in heart failure and death. Calcium/calmodulin-dependent protein kinase II delta (CaMKIId) is a key molecular mediator of adverse LV remodeling.
Cardiovascular Biomarkers in the Early Discrimination of Type 2 Myocardial Infarction
Thomas Nestelberger, MD1,2,3; Jasper Boeddinghaus, MD1,2; Pedro Lopez-Ayala, MD1,2; Thomas E. Kaier, MD, MBA, PhD4; Michael Marber, MBBS, PhD4; Vincent Gysin, MD1,2; Luca Koechlin, MD1,2,5; Ana Yufera Sanchez, MD1,2; Maria Rubini Giménez, MD1,2,6; Desiree Wussler, MD1,2; Joan Elias Walter, MD1,2; Ivo Strebel, MSc1,2; Tobias Zimmermann, MD1,2; Noemi Glarner, MD1,2; ?scar Mir?, MD2,7; F. Javier Martin-Sanchez, MD2,8; Tatjana Zehnder, MS1,2; Raphael Twerenbold, MD1,2; Dagmar I. Keller, MD9; Christian Mueller, MD1,2; for the APACE Investigators
doi : 10.1001/jamacardio.2021.0669
JAMA Cardiol. 2021;6(7):771-780
Rapid and accurate noninvasive discrimination of type 2 myocardial infarction (T2MI), which is because of a supply-demand mismatch, from type 1 myocardial infarction (T1MI), which arises via plaque rupture, is essential, because treatment differs substantially. Unfortunately, this is a major unmet clinical need, because even high-sensitivity cardiac troponin (hs-cTn) measurement provides only modest accuracy.
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease
Michelle T. Lee, MD, PharmD1,2; Dhruv Mahtta, DO, MBA1,2,3; David J. Ramsey, PhD1; Jing Liu, MD3; Arunima Misra, MD3,4; Khurram Nasir, MD, MPH5; Zainab Samad, MBBS, MHS4,6; Dipti Itchhaporia, MD7; Safi U. Khan8; Richard S. Schofield, MD9,10; Christie M. Ballantyne, MD3,11; Laura A. Petersen, MD, MPH1,2; Salim S. Virani, MD, PhD1,3,4
doi : 10.1001/jamacardio.2021.0683
JAMA Cardiol. 2021;6(7):782-790
There is a paucity of data regarding secondary prevention care disparities in women with premature and extremely premature atherosclerotic cardiovascular disease (ASCVD), defined as an ASCVD event at 55 years or younger and 40 years or younger, respectively.
Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines–Heart Failure Hospitals
Ehete Bahiru, MD1; Boback Ziaeian, MD, PhD1,2; Corrina Moucheraud, ScD3; Anubha Agarwal, MD, MSc4; Haolin Xu, BS5; Roland A. Matsouaka, PhD5,6; Adam D. DeVore, MD, MHS5; Paul A. Heidenreich, MD7; Larry A. Allen, MD, MHS8; Clyde W. Yancy, MD4,9; Gregg C. Fonarow, MD1,10,11
doi : 10.1001/jamacardio.2021.0611
JAMA Cardiol. 2021;6(7):791-800
The Centers for Medicare & Medicaid Services uses a new peer group–based payment system to compare hospital performance as part of its Hospital Readmissions Reduction Program, which classifies hospitals into quintiles based on their share of dual-eligible beneficiaries for Medicare and Medicaid. However, little is known about the association of a hospital’s share of dual-eligible beneficiaries with the quality of care and outcomes for patients with heart failure (HF).
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes
Thomas A. Zelniker, MD, MSc1; Itamar Raz, MD2; Ofri Mosenzon, MD, MSc2; Jamie P. Dwyer, MD3; Hiddo H. J. L. Heerspink, PharmD, PhD4,5; Avivit Cahn, MD2; Erica L. Goodrich, MSc2; Kyungah Im, PhD6; Deepak L. Bhatt, MD, MPH6; Lawrence A. Leiter, MD7; Darren K. McGuire, MD, MHSc8; John P. H. Wilding, MD9; Ingrid Gause-Nilsson, MD, PhD10; Anna Maria Langkilde, MD, PhD10; Marc S. Sabatine, MD, MPH6; Stephen D. Wiviott, MD6
doi : 10.1001/jamacardio.2021.0660
JAMA Cardiol. 2021;6(7):801-810
Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The relative CV efficacy and safety of dapagliflozin according to baseline kidney function and albuminuria status are unknown.
Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals
Brandon Chalazan, MD1; Denise Mol, BA1; Faisal A. Darbar, BSc1; Aylin Ornelas-Loredo1; Bahaa Al-Azzam, MD1; Yining Chen, BSc1; David Tofovic, MD1; Arvind Sridhar, MSc1; Zain Alzahrani, MD1; Patrick Ellinor, MD, PhD2; Dawood Darbar, MD1,3,4
doi : 10.1001/jamacardio.2021.0994
JAMA Cardiol. 2021;6(7):811-819
Although rare variants in cardiac ion channels, transcription factors, and myocardial structural proteins are associated with early-onset atrial fibrillation (AF) in White individuals of European descent, it remains unclear whether genetic variation also contributes to the cause of AF in those of minority ethnicity.
Association of Systolic Blood Pressure Elevation With Disproportionate Left Ventricular Remodeling in Very Preterm-Born Young Adults
Afifah Mohamed, DPhil1,2,3; Maciej Marciniak, MSc4; Wilby Williamson, MBBS, DPhil1; Odaro J. Huckstep, DPhil1,5; Winok Lapidaire, PhD1,3; Angus McCance, BA1,3; Stefan Neubauer, MD3,6; Paul Leeson, MB, PhD1,3; Adam J. Lewandowski, DPhil1,3,6
doi : 10.1001/jamacardio.2021.0961
JAMA Cardiol. 2021;6(7):821-829
Preterm-born individuals have higher blood pressure with an increased risk of hypertension by young adulthood, as well as potentially adverse cardiac remodeling even when normotensive. To what extent blood pressure elevation affects left ventricular (LV) structure and function in adults born preterm is currently unknown.
Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care
Mark Y. Chan, MBBS, PhD1,2; Karen W. L. Koh, RN, PhD2,3; Sock-Cheng Poh, RN, BSc2,3; Stephanie Marchesseau, PhD4,5; Devinder Singh, MBBS2; Yiying Han, BSc5; Faclin Ng, RN, BSc2,3; Eleanor Lim, BSc2,3; Joseph F. Prabath, MBBS6; Chi-Hang Lee, MBBS, MD1,2; Hui-Wen Sim, MBBS1; Ruth Chen, MBBS6; Leonardo Carvalho, MD, PhD7; Sock-Hwee Tan, PhD1; Joshua P. Y. Loh, MBBS2; Jack W. C. Tan, MBBS, MBA8; Karishma Kuwelker, MD9; R. M. Amanullah, MBBS8; Chee-Tang Chin, MBBS8; James W. L. Yip, MBBS2; Choy-Yee Lee, RN, MSc2; Juvena Gan, RN, MSc2; Chew-Yong Lo, RN, MSc2; Hee-Hwa Ho, MBBS6; Derek J. Hausenloy, MBBS, PhD8,10,11; Bee-Choo Tai, PhD12; A. Mark Richards, MBBS, MD, PhD1,2,13; for the IMMACULATE Investigators
doi : 10.1001/jamacardio.2020.6721
JAMA Cardiol. 2021;6(7):830-835
Is remote postdischarge treatment of low-risk patients with acute myocardial infarction by a centralized nurse clinician team under physician supervision feasible and safe?
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction
Massar Omar, MD1,2,3; Jesper Jensen, MD4,5; Mulham Ali, MD1,3; Peter H. Frederiksen, MD1,3; Caroline Kistorp, MD, PhD5,6; Lars Videb?k, MD, PhD7; Mikael Kj?r Poulsen, MD, PhD7; Christian D. Tuxen, MD, PhD8; S?ren M?ller, MSc, PhD9; Finn Gustafsson, MD, DMSci5,10; Lars K?ber, MD, DMSci5,10; Morten Schou, MD, PhD4,5; Jacob Eifer M?ller, MD, DMSci1,3,10
doi : 10.1001/jamacardio.2020.6827
JAMA Cardiol. 2021;6(7):836-840
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in patients with heart failure and a reduced ejection fraction (HFrEF). The association with cardiac remodeling has not been investigated.
Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1
Sadiya S. Khan, MD, MS1,2; Sanjiv J. Shah, MD1,3; Jennifer L. Strande, MD, PhD4; Abigail S. Baldridge, MS2; Panagiotis Flevaris, MD, PhD1; Megan J. Puckelwartz, PhD5; Elizabeth M. McNally, MD, PhD1,5; Laura J. Rasmussen-Torvik, PhD, MPH2; Daniel C. Lee, MD1,6; James C. Carr, MD7; Brandon C. Benefield, MS6; Muhammad Zeeshan Afzal, PhD4; Meadow Heiman, MS8; Sweta Gupta, MD, MS8; Amy D. Shapiro, MD8; Douglas E. Vaughan, MD6
doi : 10.1001/jamacardio.2020.6909
JAMA Cardiol. 2021;6(7):841-846
Cardiac fibrosis is exceedingly rare in young adults. Identification of genetic variants that cause early-onset cardiomyopathy may inform novel biological pathways. Experimental models and a single case report have linked genetic deficiency of plasminogen activator inhibitor-1 (PAI-1), a downstream target of cardiac transforming growth factor ?, with cardiac fibrosis.
Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population
Luis R. Lopes, PhD1,2; Nay Aung, PhD2,3; Stefan van Duijvenboden, PhD3; Patricia B. Munroe, PhD3; Perry M. Elliott, MD1,2; Steffen E. Petersen, DPhil2,3
doi : 10.1001/jamacardio.2021.0689
JAMA Cardiol. 2021;6(7):852-854
Could Flozins Be the Statins for Risk-Based Primary Prevention of Heart Failure?
Priya M. Freaney, MD1,2; Donald M. Lloyd-Jones, MD, ScM1,2; Sadiya S. Khan, MD, MSc1,2
doi : 10.1001/jamacardio.2021.1133
JAMA Cardiol. 2021;6(7):741-742
Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed
Stephen J. Greene, MD1,2; Javed Butler, MD, MPH, MBA3; Gregg C. Fonarow, MD4,5
doi : 10.1001/jamacardio.2021.0496
JAMA Cardiol. 2021;6(7):743-744
To Be or Not to Be a CaMKII Inhibitor?
Mark E. Anderson, MD, PhD1
doi : 10.1001/jamacardio.2021.0701
JAMA Cardiol. 2021;6(7):769-770
A Young Patient With Hives and Chest Pain
Maxim Ben-Yakov, MDCM1; Vigil James, MD2; Brant Slomovic, MD3,4
doi : 10.1001/jamacardio.2021.0749
JAMA Cardiol. 2021;6(7):847-848
Transthyretin Genetic Testing
Arjun Sinha, MD, MSc1,2; Elizabeth M. McNally, MD, PhD2,3,4; Sadiya S. Khan, MD, MSc1,2
doi : 10.1001/jamacardio.2021.0835
JAMA Cardiol. 2021;6(7):849-850
Statin Prescribing and Dosing—Failure Has Become an Option
Laszlo Mark, MD, PhD1; Istvan Reiber, MD, PhD2; Peter P. Toth, MD, PhD3
doi : 10.1001/jamacardio.2021.0832
JAMA Cardiol. 2021;6(7):854-855
Statin Prescribing and Dosing—Failure Has Become an Option—Reply
Srinath Adusumalli, MD, MSHP1,2,3; Mitesh S. Patel, MD, MBA1,2,4,5
doi : 10.1001/jamacardio.2021.0838
JAMA Cardiol. 2021;6(7):855
Differentiating Type 1 and Type 2 Myocardial Infarction
Marc S. Sabatine, MD, MPH1,2
doi : 10.1001/jamacardio.2021.0693
JAMA Cardiol. 2021;6(7):781
Genetic Studies of Atrial Fibrillation in Diverse Cohorts and Identification of Diverse Phenotypes Associated With Single Genes
Sadiya S. Khan, MD, MSc1,2,3; Elizabeth M. McNally, MD, PhD4,5
doi : 10.1001/jamacardio.2021.1004
JAMA Cardiol. 2021;6(7):820
